Detection of a novel familial deletion of four genes between BP1 and BP2 of the Prader-Willi/Angelman syndrome critical region by oligo-array CGH in a child with neurological disorder and speech impairment (original) (raw)

Two common classes of deletions are described in the literature in individuals with Prader-Willi/Angelman syndrome (PWS/AS): one between breakpoint 1 (BP1) to BP3 and the other between BP2 to BP3 of the PWS/AS critical region on chromosome 15q11→q13. We present here a novel observation of an approximately 253-kb deletion between BP1 and BP2 on 15q11.2, in a 3½-year-old boy, who was referred to us with a clinical suspicion of having Angelman syndrome and presenting with mental retardation, neurological disorder, developmental delay and speech impairment. Karyotype and FISH results were found to be normal. The microdeletion between BP1 and BP2 includes four genes – NIPA1, NIPA2, CYFIP1 and TUBGCP5 which was detected by a high-resolution oligonucleotide array-CGH that was further validated by a Multiplex Ligation-dependent Probe Amplification (MLPA) assay. The same deletion was observed in the father who presented with similar but relatively milder clinical features as compared to the affected son. Methylation studies by methylation-specific MLPA (MS-MLPA) of the SNRPN imprinting center (IC) showed a normal imprinting pattern, both in the patient and the father. To our knowledge a microdeletion limited only to the BP1-BP2 region has not yet been reported. The familial genetic alteration together with the striking clinical presentation in this study are interesting, but from our single case study it is difficult to suggest if the deletion is causative of some of the abnormal features or if it is a normal variant. The study however further strengthens the fact that genome-wide analysis by array CGH in individuals with developmental delay and mental retardation is very useful in detecting such hidden interstitial chromosomal rearrangements.

References

Amos-Landgraf JM, Ji Y, Wayne G, Depinet T, Wandstrat AE, et al: Chromosome breakage in Prader-Willi and Angelman syndromes involves recombination between large, transcribed repeats at proximal and distal breakpoints. Am J Hum Genet 65:370–386 (1999).

Antonarakis SE: BACking up the promises. Nat Genet 27:230–232 (2001).

Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, et al: Recent segmental duplications in the human genome. Science 297:1003–1007 (2002).

Bejjani BA, Theisen AP, Ballif BC, Shaffer LG: Array-based comparative genomic hybridization in clinical diagnosis. Expert Rev Mol Diagn 5:421–429 (2005).

Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T: Behavioural differences among subjects with Prader-Willi syndrome and type I or Type II deletion and maternal disomy. Pediatrics 113:565–573 (2004).

Chai JH, Locke DP, Greally JM, Knoll JH, Ohta T, et al: Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet 73:898–925 (2003).

Christian SL, Fantes JA, Mewborn SK, Huang B, Ledbetter DH: Large genomic duplicons map to sites of instability in the Prader-Willi/Angelman syndrome chromosome region (15q11→q13). Hum Mol Genet 8:1025–1037 (1999).

De Vries BB, White SM, Knight SJ, Regan R, Homfray T, et al: Clinical studies on submicroscopic subtelomeric rearrangements; a checklist. J Med Genet 38:145–150 (2001).

Feuk L, Carson AR, Scherer SW: Structural variation in the human genome. Nat Rev Genet 7:85–97 (2006a).

Feuk L, Marshall CR, Wintle RF, Scherer SW: Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 15 Suppl 1:R57–R66 (2006b).

Flint J, Wilkie AO, Buckle VJ, Winter RM, Holland AJ, McDermid HE: The detection of subtelomeric chromosomal rearrangements in idiopathic mental retardation. Nat Genet 9:132–140 (1995).

Gimelli G, Pujana MA, Patricelli MG, Russo S, Giardino D, et al: Genomic inversions of human chromosome 15q11→q13 in mothers of Angelman syndrome patients with class II (BP2/3) deletions. Hum Mol Genet12:849–858 (2003).

Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, et al: Detection of large-scale variation in the human genome. Nat Genet 36:949–951 (2004).

Knight SJ, Regan R, Nicod A, Horsley SW, Kearney L, et al: Subtle chromosomal rearrangements in children with unexplained mental retardation. Lancet 354:1676–1681 (1999).

Kriek M, White SJ, Bouma MC, Dauwerse HG, Hansson KB, et al: Genomic imbalances in mental retardation. J Med Genet 41:249–255 (2004).

Landers M, Calciano MA, Colosi D, Glatt-Deeley H, Wagstaff J, Lalande M: Maternal disruption of UBE3A leads to increased expression of _UBE3A_-ATS in trans. Nucleic Acids Res 33:3976–3984 (2005).

Locke DP, Segraves R, Nicholls RD, Schwartz S, Pinkel D, et al: BAC microarray analysis of 15q11→q13 rearrangements and the impact of segmental duplications. J Med Genet 41:175–182 (2004).

Lossie AC, Whitney MM, Amidon D, Dong HJ, Chen P, et al: Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J Med Genet 38:834–845 (2001).

Lupski JR: Genomic disorders: structural features of the genome can lead to DNA rearrangements and human disease traits. Trends Genet 14:417–422 (1998).

Milner KM, Craig EE, Thompson RJ, Veltman MW, Thomas NS, et al: Prader-Willi syndrome: intellectual abilities and behavioural features by genetic subtype. J Child Psychol Psychiatry 46:1089–1096 (2005).

Nygren AO, Ameziane N, Duarte HM, Vijzellar RN, Waisfisz Q, et al: Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33:e128 (2005).

Rainer S, Chai JH, Tokarz D, Nicholls RD, Fink JK: NIPA1 gene mutation causes autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet 73:967–971 (2003).

Rickman L, Fiegler H, Shaw-Smith C, Nash R, Cirigliano V, et al: Prenatal detection of unbalanced chromosomal rearrangements by array CGH. J Med Genet 43:353–361 (2006).

Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57 (2002).

Sebat J, Lakshmi B, Troge J, Alexander J, Young J, et al: Largescale copy number polymorphism in the human genome. Science 305:525–528 (2004).

Shaw-Smith C, Redon R, Rickman L, Rio M, Willatt L, et al: Microarray based comparative genomic hybridization (array-CGH) detects submicroscopic chromosomal deletions and duplications in patients with learning disabilities/ mental retardation and dysmorphic features. J Med Genet 41:241–248 (2004).

Varela MC, Kok F, Otto PA, Koiffmann CP: Phenotypic variability in Angelman syndrome: Comparison among different deletion classes and between deletion and UPD subjects. Eur J Hum Genet 12:987–992 (2004).

Veltman JA, Schoenmakers EFPM, Eussen BH, Janssen I, Merkx G, et al: High throughput analysis of subtelomeric chromosome rearrangements by use of array-based comparative genomic hybridization. Am J Hum Genet 70:1269–1276 (2002).

Vermeesch JR, Melotte C, Froyen G, Van Vooren S, Dutta B, et al: Molecular karyotyping: array CGH quality criteria for constitutional genetic diagnosis. J Histochem Cytochem 53:413–422 (2005).

Vissers LE, de Vries BB, Osoegawa K, Janssen IM, Feuth T, et al: Array-based comparative genomic hybridization for the genomewide detection of submicroscopic chromosomal abnormalities. Am J Hum Genet 73:1261–1270 (2003).

2007

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

You do not currently have access to this content.

Digital Version

Pay-Per-View Access

$39.00

1 Karger Article Bundle Token

$150

Rental

This article is also available for rental through DeepDyve.

Detection of a novel familial deletion of four genes between BP1 and BP2 of the Prader-Willi/Angelman syndrome critical region by oligo-array CGH in a child with neurological disorder and speech impairment (original) (raw)

Abstract

References

Sign in

Digital Version